About BioAge Labs
BioAge Labs is a publicly listed company based in Vallejo (United States) founded in 2015 by Eric Morgen. Bioinformatics platform is provided for biomarkers and drug discovery. BioAge Labs has raised $293.9 million across 4 funding rounds from investors including Amgen, Kaiser Permanente and AARP. The company has 64 employees. Its website bioagelabs.com draws about 10 thousand monthly visits. BioAge Labs offers products and services including NLRP3 Program, APJ Program, and Discovery Platform. Its focus areas include HealthTech, Life Sciences Tech, Research & Development and Drug Informatics. Its competitors include Helix, Benchling and NantHealth; 3 of its 3 listed competitors have raised funding.
Company details
BioAge Labs was founded in 2015 in Vallejo, United States, within the biotechnology sector. A bioinformatics platform is operated to support biomarker identification and drug discovery processes. Computational biology methods are utilized alongside AI technology to analyze genomic data for developing new therapeutic candidates. The companys efforts are centered on enhancing precision in medicine discovery through data-driven approaches.
- Headquarters Vallejo, United States
- Employees 64
- Founders Eric Morgen
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Website bioagelabs.com
- Social LinkedIn X
- Legal Name Bioage Labs, Inc.
- Annual Revenue$8.99 M (USD)as on Dec 31, 2025
- Net Profit-$80.61 M (USD)-13.35as on Dec 31, 2025
- EBITDA-$92.57 M (USD)-18.63as on Dec 31, 2025
- Total Equity Funding$293.9M (USD)
in 4 rounds
- Latest Funding Round$170M (USD), Series D
Feb 2024
- InvestorsAmgen
& 23 more
- Employee Count64
Products & Services of BioAge Labs
BioAge Labs offers a comprehensive portfolio of products and services, including NLRP3 Program, APJ Program, and Discovery Platform.
Targets inflammation linked to obesity and metabolic issues
Acts as exercise mimetic for weight loss in obesity
Analyzes multi-omics data for aging and disease mediators
Funding Insights of BioAge Labs
BioAge Labs has successfully raised a total of $293.9M across 4 strategic funding rounds. The most recent funding activity was a Series D round of $170 million completed in February 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $293.9M
- Total Rounds 4
- Last Round Series D — $170M
- First Round $10.9M
(Jul 2017)
- Investors Count 24
All 4 funding rounds of BioAge Labs with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2024 | $170M | Series D | – | Sofinnova Investments | |
| Dec 2020 | $90M | Series C | – | a16z, Elad Gil | |
| Jan 2019 | $23M | Series B | – | Felicis Ventures | |
| Jul 2017 | $10.9M | Series A | – | a16z |
24 investors in total: 22 institutional and 2 angel.
Investors in BioAge Labs
BioAge Labs has secured backing from 24 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include Amgen, Kaiser Permanente and AARP.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Biotech funding, drug development support, and investment in life sciences. | sofinnova.com | |||
Private equity firm focused on life science sector | longitudecapital.com | Menlo Park, United States | ||
Life Sciences focused VC firm investing in the US | 2010 | rtwfunds.com | New York, United States | |
Venture capital fund focused on early-stage healthcare startups | svhealthinvestors.com | Boston, United States | ||
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields. | 1989 | orbimed.com | New York, United States | |
Early- to growth-stage startups are targeted for venture capital investments. | oup.vc | Bala Cynwyd, United States | ||
Early-stage life sciences investments are targeted in the healthcare sector. | lillyventures.com | Indianapolis, United States | ||
Venture capital investments in technology sectors are handled by Andreessen Horowitz. | a16z.com | |||
A global healthcare investment firm supporting innovative therapeutic companies. | 2017 | pivotallifesciences.com | San Francisco, United States | |
A venture firm based in San Francisco and New York, investments are made in technology companies. | caffeinatedcapital.com | San Francisco, United States |
Investor details for BioAge Labs
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of BioAge Labs
42 people are tracked at BioAge Labs (16 in leadership, 15 in board & advisors, 11 in team); the tracked headcount is 64.
| Name | Role | Group |
|---|---|---|
Eric Morgen | Co-Founder & COO | Leadership |
BJ Sullivan | Chief Strategy Officer | Leadership |
Robert Hughes | VP, Biochemistry | Leadership |
Shane Barton | VP, Finance | Leadership |
Paul Rubin | EVP, Research & CMO | Leadership |
Dov Goldstein | Chief Financial Officer | Leadership |
Kristen Fortney | Co-Founder & CEO | Leadership |
Yan Wang | VP, Translational Aging Biology | Leadership |
Ann Neale | Chief Development Officer | Leadership |
Matt Banicki | Senior Director - In Vivo Operations | Leadership |
Julie Magnuson Gammelgard | Senior Vice President, People | Leadership |
Ling Chen | Sr Director Of Clinical Science | Leadership |
Ivy Chen | Director, Business Development | Leadership |
Sangita Ghosh | Sr. Vice President, CMC | Leadership |
Jill Aremia | Vp, R&d Operations | Leadership |
Chris Patil | VP, Media | Leadership |
Pankaj Agarwal | Advisor, Drug Discovery Bioinformatics | Board & advisors |
William Evans | Advisor | Board & advisors |
Joe Betts-Lacroix | Advisor | Board & advisors |
Klaus Klumpp | Advisor | Board & advisors |
22 more people are available in the full profile.
Complete people profiles for BioAge Labs
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of BioAge Labs
BioAge Labs is a publicly listed company on the NASDAQ with ticker symbol BIOA in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date26 Sep 2024
- Listed onNASDAQ: BIOA
- Listed entityBioAge Labs, Inc.
- Exchange sectorHealth technology
- ISINUS09077V1008
- Share price$5.57 (-6.23% on the day) · 2026-10-13
- Market capitalisation$255.6M
- EPS (diluted, trailing year)$-2.39
- Volume (last session)638,502
Financials of BioAge Labs
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $9.0M | -$80.6M | -$92.6M |
| 2024 | -$71.1M | -$78.0M | |
| 2023 | -$63.9M | -$48.2M | |
| 2022 | -$39.7M | -$39.8M |
Detailed financial statements for BioAge Labs
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of BioAge Labs
4 dated milestones of BioAge Labs across 9 years, from founding to its latest funding, stage changes and deals.
- Founded BioAge Labs is founded.
- Funding First funding round of $10.9M.
- Funding Latest funding round, Series D, of $170.0M.
- IPO Lists on the stock exchange (IPO).
Competitors of BioAge Labs
BioAge Labs has 3 listed competitors in our database, 3 of them funded. They include Helix, Benchling and NantHealth.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| helix.com | 2015 | San Francisco, United States | $435M | Genomic database for clinical research is provided. | ||
| benchling.com | 2012 | San Francisco, United States | $411.9M | 640 | Cloud-based bioinformatics platform is offered for biotech research. | |
| nanthealth.com | 2007 | El Segundo, United States | $607.58M | 380 | Bioinformatics platforms are provided for cancer treatment identification. |
Detailed competitors of BioAge Labs
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of BioAge Labs
The website of BioAge Labs (bioagelabs.com) receives about 10.3K visits a month and ranks #1,700,803 among all websites worldwide, #2,299 in Biotechnology and Pharmaceuticals.
- Monthly visits10.3K
▼ 32.8% vs previous month
- Unique visitors6.9K
per month
- Global rank#1,700,803
among all websites
- Category rank#2,299
Health · Biotechnology and Pharmaceuticals
- Bounce rate43%
- Pages per visit1.6
- Average visit1 min 08 sec
- DevicesDesktop 50% · Mobile 50%
Websites whose visitors overlap most with BioAge Labs. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| bioage.com | 100% | 4.1K | #3,599,948 | View details | |
| fiercepharma.com | 61% | #124,066 | View details | ||
careers.ncbiotech.org | careers.ncbiotech.org | 47% | #857,423 | – |
Top companies in Orthopedics
3 companies that operate in the same segment as BioAge Labs (Orthopedics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Provider of high-frequency spinal cord stimulation implants | 2006 | Menlo Park, California, United States | USD 154.1 M | USD 353.08 M | 1,215 | |
Developer of therapies for the treatment of musculoskeletal disorders | 2007 | Woburn, Massachusetts, United States | USD 62 M | USD 85.55 M | 692 | |
Antibody-siRNA complexes are developed for cancer treatment. | 2012 | San Diego, California, United States | USD 142.54 M | USD 10.9 M | 391 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Bioage Labs
Complete news archive for BioAge Labs
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about BioAge Labs
BioAge Labs was founded in 2015 and raised its 1st funding round 2 years after it was founded.
BioAge Labs is headquartered in Vallejo, United States. It is registered at Vallejo, California, United States.
BioAge Labs is a funded company, having raised a total of $293.9M across 4 funding rounds to date. The company's 1st funding round was a Series A of $10.9M, raised on Jul 2017.
BioAge Labs has 64 employees.
Annual revenue of BioAge Labs is $8.99M as on Dec 31, 2025.
BioAge Labs was founded in 2015 in Vallejo, United States, within the biotechnology sector. A bioinformatics platform is operated to support biomarker identification and drug discovery processes. Computational biology methods are utilized alongside AI technology to analyze genomic data for developing new therapeutic candidates. The companys efforts are centered on enhancing precision in medicine discovery through data-driven approaches.
BioAge Labs's top competitors include Helix, NantHealth and Benchling.
BioAge Labs offers NLRP3 Program, APJ Program, and Discovery Platform.
Yes, BioAge Labs is publicly traded on NASDAQ under the ticker symbol BIOA.
BioAge Labs has 24 investors. Key investors include Amgen, Kaiser Permanente, AARP, Khosla Ventures, and Orbimed.